The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.

Sebastian Ochsenreither,Ulrich Keilholz,Konrad Klinghammer,Christina Dicke,Maxim Kebenko,Elena Garralda,Josep Tabernero,Ignacio Matos,Domenica Lorusso,Francesco Raspagliesi,Luca Gianni,Gianluca Del Conte,Beate Habel,Hans Baumeister,Riccardo Belli,Alfredo Zurlo,Walter Fiedler

The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.

2018

Sebastian Ochsenreither
Ulrich Keilholz
Konrad Klinghammer
Christina Dicke
Maxim Kebenko
Elena Garralda
Josep Tabernero
Ignacio Matos
Domenica Lorusso
Francesco Raspagliesi
Luca Gianni
Gianluca Del Conte
Beate Habel
Hans Baumeister
Riccardo Belli
Alfredo Zurlo
Walter Fiedler

TPS2596Background: TO (CetuGEX) is a second-generation anti-EGFR antibody that specifically binds to EGFR and acts as a competitive antagonist at the ligand binding site. GAT (PankoMab-GEX) is a no...

Keywords:

MUC1
Pathology
Cancer research
Medicine
Antibody
Ligand (biochemistry)
in patient
Competitive antagonist

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations